Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI statements evaluated are about market sizing and the absence of evidence-based figures, which are not prescribing-information claims. The only drug-label-adjacent statement (Revatio is sildenafil and is used for PAH) is consistent with the provided label excerpts.
Category Scores
Accurate Statements
Revatio is the brand name for sildenafil.
Label excerpts identify REVATIO (sildenafil) as the drug; active ingredient stated as sildenafil (as sildenafil citrate).
Sildenafil (Revatio) is used for pulmonary arterial hypertension (PAH).
Label excerpt (1 INDICATIONS AND USAGE): REVATIO is indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults and pediatric patients 1 to 17 years old.
The response does not provide evidence-based figures for Revatio’s market size (e.g., global sales/revenue, units, or patient volume).
Not a prescribing-information claim; no contradiction in provided label excerpts.
Market-research reports may break out the PAH treatment segment and the branded sildenafil portion.
Not a prescribing-information claim; no contradiction in provided label excerpts.
Unsupported Statements
Market size for Revatio can vary depending on whether analysts count global versus a specific country.
Not supported or contradicted by the provided FDA prescribing information excerpts because it concerns market sizing, not labeled clinical use, dosing, safety, or interactions.
Market size for Revatio can vary depending on whether analysts count all sildenafil versus only Revatio-branded sales.
Not supported or contradicted by the provided FDA prescribing information excerpts because it concerns market sizing methodology.
Market size for Revatio can vary depending on whether analysts measure prescription sales, total revenue, or patient numbers.
Not supported or contradicted by the provided FDA prescribing information excerpts because it concerns market sizing methodology.
Prescription/sales databases often provide market-size inputs for branded products and therapeutic indications.
Not supported or contradicted by the provided FDA prescribing information excerpts because it concerns external market data sources.
Company filings or investor materials may disclose a brand separately.
Not supported or contradicted by the provided FDA prescribing information excerpts because it concerns external corporate reporting.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No dosing, contraindications, precautions, or safety guidance was asserted. The only medical/label-adjacent claim (PAH indication) is consistent with the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several statements are about market sizing methodology and are not addressed by prescribing information; they cannot be verified against the provided FDA label excerpts.
Suggested Improvement
Limit statements to what the label supports (e.g., indication, dosing, contraindications, warnings) and clearly avoid or qualify non-label market sizing assertions when evaluating against prescribing information.